Erica R. Vander Mause

Erica R. Vander Mause

Auto-generated profile, based on publicly available information

Erica R. Vander Mause

Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2022 in Trends in Biotechnology
Verified
Journal Article
Closed access
EMErica R. Vander Mause
Erica R. Vander Mause
DADjordje Atanackovic
Djordje Atanackovic
CLCarol S. Lim
Carol S. Lim
TLTim Luetkens
Tim Luetkens

19 July 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
EMErica R. Vander Mause
Erica R. Vander Mause
JBJillian M. Baker
Jillian M. Baker
KDKenneth A. Dietze
Kenneth A. Dietze
SRSabarinath V. Radhakrishnan
Sabarinath V. Radhakrishnan
TIThierry Iraguha
Thierry Iraguha
TLTim Luetkens
Tim Luetkens
T cells expressing chimeric antigen receptors (CARs) have shown remarkable therapeutic activity against different types of cancer. However, the wider use of CAR T cells has been hindered by the potential for life-threatening toxicities due to on-target off-tumor killing of cells expressing low amounts of the target antigen. CD229, a signaling lymphocyte-activation molecule (SLAM) family member, has previously been identified as a target for CAR T cell–mediated treatment of multiple myeloma (MM) due to its high expression on the surfaces of MM cells. CD229 CAR T cells have shown effective clearance of MM cells in vitro and in vivo. However, healthy lymphocytes also express CD229, albeit at lower amounts than MM cells, causing their unintended targeting by CD229 CAR T cells. To increase the selectivity of CD229 CAR T cells for MM cells, we used a single amino acid substitution approach of the CAR binding domain to reduce CAR affinity. To identify CARs with increased selectivity, we screened variant binding domains using solid-phase binding assays and biolayer interferometry and determined the cytotoxic activity of variant CAR T cells against MM cells and healthy lymphocytes. We identified a CD229 CAR binding domain with micromolar affinity that, when combined with overexpression of c-Jun, confers antitumor activity comparable to parental CD229 CAR T cells but lacks the parental cells’ cytotoxic activity toward healthy lymphocytes in vitro and in vivo. The results represent a promising strategy to improve the efficacy and safety of CAR T cell therapy that requires clinical validation.

14 July 2022 in Blood
Verified
Journal Article
Open access
PDF file
DADjordje Atanackovic
Djordje Atanackovic
TLTim Luetkens
Tim Luetkens
DODestiny Omili
Destiny Omili
TIThierry Iraguha
Thierry Iraguha
FLForat Lutfi
Forat Lutfi
SDSaurabh Dahiya
Saurabh Dahiya
Patients receiving CD19 CAR T-cell therapy for relapsed/refractory lymphoma experience prolonged and profound B-cell aplasia and hypogammaglobulinemia, placing them at a higher risk for severe COVID-19. Independently, Oh et al and Atanackovic et al demonstrate that despite attenuated humoral response to mRNA-based vaccines, patients demonstrate normal or heightened functional T-cell responses, including antiviral T-cell activity against SARS-CoV-2 variants including Omicron. Collectively, these data reinforce the importance of COVID-19 vaccination following CD19 CAR T-cell therapy, despite long-term B-cell aplasia.

16 December 2021 in Communications Biology
Verified
Journal Article
Open access
PDF file
DADjordje Atanackovic
Djordje Atanackovic
SAStephanie V. Avila
Stephanie V. Avila
FLForat Lutfi
Forat Lutfi
Diego de Miguel-PerezDiego de Miguel-Perez
Diego de Miguel-Perez
XFXiaoxuan Fan
Xiaoxuan Fan
TLTim Luetkens
Tim Luetkens
In light of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variants potentially undermining humoral immunity, it is important to understand the fine specificity of the antiviral antibodies. We screened 20 COVID-19 patients for antibodies against 9 different SARS-CoV-2 proteins observing responses against the spike (S) proteins, the receptor-binding domain (RBD), and the nucleocapsid (N) protein which were of the IgG1 and IgG3 subtypes. Importantly, mutations which typically occur in the B.1.351 “South African” variant, significantly reduced the binding of anti-RBD antibodies. Nine of 20 patients were critically ill and were considered high-risk (HR). These patients showed significantly higher levels of transforming growth factor beta (TGF-β) and myeloid-derived suppressor cells (MDSC), and lower levels of CD4+ T cells expressing LAG-3 compared to standard-risk (SR) patients. HR patients evidenced significantly higher anti-S1/RBD IgG antibody levels and an increased neutralizing activity. Importantly, a large proportion of S protein-specific antibodies were glycosylation-dependent and we identified a number of immunodominant linear epitopes within the S1 and N proteins. Findings derived from this study will not only help us to identify the most relevant component of the anti-SARS-CoV-2 humoral immune response but will also enable us to design more meaningful immunomonitoring methods for anti-COVID-19 vaccines.